CDK4/6-IN-9

CDK4/6-IN-9 (compound 10) is a selective CDK4/6 inhibitor with an IC50 of 905 nM for CDK6/cyclin D1. CDK4/6-IN-9 has the potential for multiple myeloma (MM) research[1].

Product Specifications

CAS Number

[2688098-02-2]

UNSPSC

12352005

Target

CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cdk4-6-in-9.html

Concentration

10mM

Purity

99.46

Solubility

DMSO : 16.67 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CN1C=C(C2=NC(NC3=NC=C(CN4CCNCC4)C=C3)=NC=C2F)C5=CC=CN=C51

Molecular Formula

C22H23FN8

Molecular Weight

418.47

References & Citations

[1]Kai Yuan, et al. Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma. Eur J Med Chem. 2022 Jan 15;228:114024.